BY Maria Outze
-
Genmab received USD 12.5m in payment from Novo Nordisk in 2025
Genmab’s landmark repayments from its companions completed USD 97m in 2025.
-
Novo Nordisk sees continued boost in US sales of Wegovy tablet
New information reveals that Novo Nordisk released 52,299 brand-new prescriptions for the Wegovy tablet computer in the United States recently.
-
Genmab is convinced that pipeline will withstand looming patent gap
Adhering To the USD 8bn purchase of Merus, Genmab’s chief executive officer turns down more procurements in the coming years. “We do not require to,” states Jan v…
-
ALK’s chief scientific officer resigns
Henriette Mersebach is leaving her placement as EVP of R&D at ALK by shared arrangement.
-
Genmab drops diversity targets for senior management
The pharmaceutical firm did not accomplish its sex variety targets for 2025 and is currently dropping them for elderly monitoring, while preserving a target for monitoring listed b…
-
Leo Pharma hit by headwinds in China: “We haven’t launched anything in more than a decade”
Leo Pharma will certainly once more get along with brand-new launches in China after encountering headwinds in 2025. The chief executive officer has high assumptions for 2 items sp…
-
Genmab faces “decisive year” in 2026 with key trial results on the horizon
According to Genmab’s chief executive officer, as much as 6 medical tests in 2026 can be crucial for prospective brand-new launches of prospective smash hits in 2027.
-
Genmab received USD 12.5m in payment from Novo Nordisk in 2025
Genmab’s milestone payments from its partners totaled USD 97m in 2025.
-
FDA rejection of Moderna vaccine raises uncertainty for industry
According to an analyst, growing vaccine skepticism during the Trump administration may raise development costs for new vaccines.
-
Fujifilm expands production in the UK: “A significant investment”
This is Fujifilm Biotechnologies’ “biggest financial investment ever before” in the UK. To name a few points, the big financial investment will certainly sustain …
